Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Androgen Deprivation Therapy in Prostate Cancer

Studying associations with dementia

Publish date:: December 15, 2015

There is an association between the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer and an increased risk of Alzheimer disease in a general population cohort, according to a study of 16,888 patients with prostate cancer, including 2,397 receiving ADT during a median follow-up of 2.7 years. Researchers found:

• Propensity score-matched analysis and traditional multivariable-adjusted Cox regression analysis both supported a statistically significant association between ADT use and Alzheimer disease risk.

• Alzheimer disease risk increased significantly with increasing duration of ADT use.

Citation: Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Androgen deprivation therapy and future Alzheimer’s disease risk. [Published online ahead of print December 7, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.63.6266.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,